Stefan Hutwimmer

Title: The Innovations of Stefan Hutwimmer

Introduction

Stefan Hutwimmer is a notable inventor based in Kundl, Austria. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acids. His work has implications for medical advancements, especially in the production of human granulocyte-colony stimulating factor (G-CSF).

Latest Patents

Stefan Hutwimmer holds a patent for a DNA coding sequence for human G-CSF. This invention relates to a nucleic acid encoding human G-CSF, where the first leucine residue on the N-terminal end is encoded by a codon other than the CTG/CUG codon. The patent specifies that the nucleic acid does not comprise the sequences according to SEQ ID NO: 1, 2, 3, or 4. Additionally, it includes a nucleic acid that is 100% complementary to the aforementioned nucleic acid, as well as vectors and host cells that incorporate these nucleic acids. The invention also outlines methods for producing human G-CSF using these nucleic acids, vectors, and host cells, along with the resulting G-CSF compositions.

Career Highlights

Stefan Hutwimmer is currently associated with Sandoz AG, a global leader in generic pharmaceuticals and biosimilars. His work at Sandoz AG has allowed him to focus on innovative solutions in the biotechnology sector. His patent reflects his commitment to advancing medical science and improving therapeutic options.

Collaborations

Stefan has collaborated with notable colleagues such as Clemens Achmüller and Johann Holzmann. These collaborations have likely contributed to the success of his research and innovations in the field.

Conclusion

Stefan Hutwimmer's contributions to biotechnology, particularly through his patent for a DNA coding sequence for human G-CSF, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and therapies.